Latest Breaking News On - Michael soldan - Page 1 : comparemela.com

Polpharma Biologics gets greenlight for first multiple sclerosis biosimilar in Europe

Polpharma Biologics, an international biotech company developing and manufacturing biosimilars, has announced that the European Commission (EC) has approved Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.

Polpharma Biologics gets FDA green light for multiple sclerosis treatment

Polpharma Biologics, a biotech company developing and manufacturing biosimilars, has announced that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko.

Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis

Polpharma Biologics Announces FDA Approval of Tyruko® -  First And Only Approved Biosimilar to Tysabri® for Relapsing Forms of Multiple SclerosisAMSTERDAM, The Netherlands, August 25, 2023 / B3C newswire / Polpharma Biologics, an international biotech company dedicated to the development and ma.

Sandoz's Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

Sandoz's Tyruko biosimilar granted FDA approval to treat relapsing MS